CTRI/2009/091/000774已完成1 期
A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics after Multiple Ascending Oral Doses of AZD1656 in subjects with T2DM treated with Metformin
AstraZeneca AB, 151 85 Södertälje, Sweden0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female (with non child-bearing potential)
- •- Diagnosed diabetes Mellitus patientstreated with metformin alone or one other anti-diabetic drugs. Stable blood sugar control indicated by no changed treatment within 3 months prior to study start.
- •- HbA1c <11 % at screening (HbA1c value according to international DCCT standard)
排除标准
- •- Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP
- •- History of ischemic heart disease, stroke, transitorisk ischemic attack or symptomatic peripheral vascular disease
- •- Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µg in Healthy Adolescents Aged 11 to 18 YearsThe test is a vaccine. The subjects are healthy adolescents.MedDRA version: 14.1Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-007789-51-PLPfizer Inc715
进行中（未招募）
不适用
A clinical study to test the safety and immune response of a vaccine against a bacteria causing meningitis B at doses of 60 µg, 120 µg, and 200 µg in healthy adolescents aged 11 to 18 YearsPrevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.MedDRA version: 17.1Level: LLTClassification code 10004049Term: Bacterial meningitisSystem Organ Class: 100000004862EUCTR2008-007789-51-Outside-EU/EEAWyeth Research Division of Wyeth Pharmaceuticals Inc.539
Unknown
2 期
A clinical Study to assess the Efficacy and Safety of Ursodiol Injection in covid-19 patientsCTRI/2021/11/038307Shilpa Medicare Limited16
招募中
不适用
Trial of Tadalafil for Duchenne Muscular DystrophyCongenital malformations, deformations and chromosomal abnormalitiesKCT0000977Eli Lilly Korea13
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue SarcomaNL-OMON47908Eli Lilly16